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Patients with terminal cardiac or renal disease have few
therapeutic options besides organ transplantation. Optimally,
cell therapies would be used both in acute and chronic stages
of such diseases. In the injured myocardium, the main
therapeutic goal is reestablishment of adequate perfusion
and cardiac output. This can be achieved by stem cell (SC)
infusions, and currently several clinical trials have provided
promising results. Considering the heart’s low intrinsic
capacity for regeneration and its paucity of resident cardiac
SCs, we believe that induction of angiogenesis must be the
primary goal, thereby promoting activation of resident SCs as
well as mobilization of perivascular mesenchymal SCs that
can mediate myocardial regeneration. Renal tissue, in
contrast to the myocardium, has a high intrinsic capacity to
respond to injuries and thus repair itself. Infusion of bone
marrow (BM) cells or of their sub-populations protects the
injured renal tissue and elicits immediate activation and
proliferation of resident cells, which are able to undertake
repair and regeneration of structures of both mesenchymal
and epithelial origin. Experimental evidence indicates that
infused cells function essentially through paracrine
pathways, decreasing inflammation and fibrosis. In both
severe cardiac and renal disorders, cell therapies appear to
be a promising therapeutic option.
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Cardiovascular diseases are the leading cause of morbidity
and mortality throughout the world. Despite significant
progress in cardiovascular medicine, mortality rates have
remained steady during the past decade. Similarly, the
number of patients developing end-stage renal disease is
steadily increasing. In both groups of diseases, transplanta-
tion of the organ is frequently the only therapeutic option,
which is, however, hampered because of the limited avail-
ability of donors and the complications associated with allo-
geneic transplantation. Cell therapies have been proposed in
both scenarios as a promising alternative therapy and, at least
in cardiovascular diseases, numerous experimental studies
and clinical trials have provided promising results. Although
we are still far from understanding all of the mechanisms
involved, most scientists would agree that in cardiology there
is no longer a question of whether cell therapies should be
used in patients, but rather how they should be used.1
In the repair of both acute cardiac ischemic lesions and
their late consequences, such as remodeling and fibrosis
leading to terminal myocardial insufficiency, two main goals
are being pursued: (1) revascularization of the ischemic heart
tissue, and (2) reestablishment of normal myocardial
contractility. As virtually every cardiomyocyte requires a
physical contact with a blood capillary, the two goals are
closely related. In addition, the collective contractile work of
cardiomyocytes must be coordinated, which requires electric
coupling of individual cardiomyocytes.
Pioneering studies on cardiac cell therapies have used
implants of skeletal muscle cell progenitors for the reestab-
lishment of cardiac contractility.2 Although this has been
partly achieved, and the feasibility of cell therapy of the
injured myocardium has been demonstrated, incomplete
coordination of cell contraction and occasional ventricular
fibrillation have raised safety concerns. Subsequent studies
have mainly used bone marrow (BM)-derived cells, either the
whole mononuclear fraction or selected cell sub-popula-
tions.3 The overall impression is that most clinical studies,
some of which include large numbers of controls, have
reported benefits to patients, often with a significant long-
term improvement of their clinical state.4
Studies with sex-mismatched heart or BM transplants
have shown some evidence of a potential direct participation
of BM-derived cells in the generation of new cardio-
myocytes.5 However, the reported numbers of differentiated
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and engrafted stem cells (SCs) are very low and insufficient to
explain the observed clinical improvements. One of the
proposed mechanisms for neo-cardiomyogenesis has been
the fusion of implanted cells with resident cardiac cells;
however, this hypothesis has not received further experi-
mental support.
Two mechanisms of the observed long-term improvement
of heart function after cell therapy have been proposed,
potentially functioning together: cardiomyogenesis and
angiogenesis. Despite the fact that the spontaneous regenera-
tion capacity of the myocardium is quite low, it has been
convincingly shown that resident heart SCs are present
within the myocardium, and that they can participate
in heart regeneration.6 An additional type of SC was
subsequently identified, dwelling in the pericardium. In
embryogenesis, the coronary vasculature derives from the
pericardium, and these pericardial cells are thought to
support the regeneration of both cardiac blood vessels and
cardiomyocytes.7 To boost the physiologically low capacity of
cardiac regeneration, effective cell therapies should provide
either an increased number of SCs or the additional stimuli
to promote intrinsic SC activation and proliferation, together
resulting in efficient heart regeneration after an acute infarct
and in secondary chronic heart failure.
The number of SCs that do differentiate into cardiomyo-
cytes after injection is rather low. However, the observed
beneficial effects can be quite longstanding. In our experi-
ence, improvement of heart function was still observed after
12 months post-therapy for severe heart failure,8 and in a
recent 5-year follow-up of the group all patients were still
well. From this follows the fact that the introduced cells must
elicit a long-term regeneration process, which may work by
stimulating resident cell progenitors. The required stimuli
may be derived from implanted BM-derived cells, which
have been shown to produce a broad set of cytokines that
stimulate SC proliferation, commitment, and differentiation.
They could function through paracrine pathways. Currently,
this mechanism of myocardium repair is considered a
plausible explanation for the favorable outcome of cardiac
cell therapies.9
Alternatively, angiogenesis may be intimately involved in
cardiomyogenesis by facilitating myocardial regeneration.
Data on sustained angiogenesis were reported in a histo-
logical study of heart tissue from a patient who died from
unrelated causes 11 months after transendocardial cell
therapy.10 Intense and late angiogenesis in fibrotic cicatricial
areas was associated with decreased density of collagen
matrix and with proliferation and hyperplasia of pericytes.
Moreover, these cells were shown to express myocardial
cytoskeleton markers while still located within the blood
vessel walls, and even more so after migrating from the vessel
wall into the adjacent myocardium, which was rich in very
small cardiomyocytes, suggestive of neo-cardiomyogenesis.
Both requirements for effective clinical heart therapy were
thus met: angiogenesis and cardiomyogenesis. The increasing
evidence showing that perivascular pericytes have properties
of mesenchymal stem cells (mSCs) is consistent with this
hypothesis.11 Generation of endothelial cells, pericytes,
vascular smooth muscle cells, and other muscle cell
progenitors are intrinsic properties of mSCs. When blood
vessel stabilization is carried out by pericytes, angiogenesis is
a self-sustained and continued process.12 The hypothesis that
the long-term regeneration of heart tissue is mediated by
local mesenchymal cells, potentially associated with mobi-
lization of resident cardiac progenitors, may thus explain, at
least in part, the observed clinical results.
The major cell lineages relevant for cardiac repair, namely
blood vessel cells and cardiomyocytes, belong to the same
mesenchymal cell family and may originate from common
SCs. These cells are present in the BM mononuclear fraction
and can undergo long-term proliferation and differentiation.
In contrast, renal tissue contains differentiated cells of diverse
embryonic origins, with complex structures associated with
blood vessels and connective tissue. To sustain proper renal
function, these cells must maintain their functional relation-
ship and the spatial order. Another major difference is the
fact that renal tissue is quite efficient in spontaneous repair of
less severe acute lesions.
Similar to cardiac tissue, sex-mismatched kidney trans-
plants have also shown rare tubular epithelial cells of BM
origin, suggesting the possibility of transdifferentiation.13 As
in cardiac repair, very low level of fusion of administered
precursor cells with target cells in the kidney, potentially
contributing to organ repair, has also been reported. Thus,
indirect effects of cell therapies have to be considered, and
specific nephronal segments that show engraftment of
exogenous cells need to be further examined.
Since 2001, several protocols of BM cell infusion in
diverse models of kidney injury have shown that BM stem/
progenitor cells can differentiate into various renal cells,
particularly those of mesenchymal or vascular origin,
including mesangial cells, and glomerular or peritubular
endothelial cells.14 Moreover, differentiation of administered
cells into tubular epithelial cells and podocytes was reported,
independently of the type of BM cell fraction or kidney
injury.15 Similar to myocardial regeneration, further studies
have proposed that BM cells function mainly on the
intra-renal pool of SCs. The kidney contains, as has been
reported, numerous resident SCs localized at several sites: in
the renal papilla, among tubular epithelial cells, Bowman’s
capsule, and medullary vascular bundles.16 Nestin, a multi-
lineage marker, has been proposed to label progenitor
cells and to help with the identification of this cell population
in the kidney. Nestin-expressing cells were localized in
the renal papilla and along the vasa recta in the medulla
under normal conditions, but they migrated, follow-
ing ischemic injury, from the papilla/medulla to the
cortex.17 This finding is consistent with studies that
demonstrated that renal SCs enter the cell cycle during self-
repair following ischemic injury, and quickly ‘disappearing’
from the papilla because of out-migration and not caused by
their apoptosis.
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In principle, mSCs can directly differentiate into cells of
the same lineage, that is, glomerular mesangial or blood
vessel cells. However, several models have shown that their
participation in renal regeneration was only indirect, with a
considerable improvement of renal function in several
models of injury. After injection of a lineage-negative BM
cell fraction that contains mSCs, or purified mSCs,18 their
beneficial effects were mediated by increased tubular cell
proliferation, decrease in tubular apoptosis, anti-inflamma-
tory effects, and angiogenic stimuli.
Paracrine factors secreted by mSCs might explain their
beneficial effects in acute kidney injury. These enhance
endothelial cell proliferation and differentiation. When mSCs
were infused just before ischemia/reperfusion injury, these
cells quickly homed to the renal microvascular circulation,
and led to decreased endogenous cell apoptosis in regions
that contained mSCs.16
Our group has recently demonstrated that the infusion
of BM mononuclear cells had a renoprotective effect in
unilateral ureteral obstruction in animals. After 14 days of
obstruction, these animals showed an enhancement of
tubular proliferation, decrease in tubular cells apoptosis,
and mobilization of nestin-positive cells into the interstitial
and peritubular spaces, without major incorporation of the
labeled donor cells into recipient renal tissue.
One of the major concerns in cell therapies that use
mesenchymal progenitors is a potential increase of fibrosis
mediated by infiltrating myofibroblasts, as it has been
suggested that one of the possible origins of myofibroblasts
is the BM. This was concluded from several experiments that
demonstrated that myofibroblasts and fibroblasts were
thought to originate from BM cells after their transplantation,
as well as from renal resident stem/progenitor cells.19 Although
conversion of nestin-positive cells into myofibroblasts has been
reported, we observed a decrease in both myofibroblasts and
the degree of fibrosis. An increase in peritubular capillaries
with some nestin-positive cells was observed, suggesting an
increased angiogenesis. Similar to the cardiac fibrotic tissue, in
which we observed a decreased density of collagen after cell
therapy, the augmented angiogenesis may be associated with a
decrease in fibrosis, likely mediated by activation of metallo-
proteinases that are associated with blood vessel growth.
Another concern is associated with the use of other
sources of mSCs, notably those derived from adipose tissue.
As cells infused into the kidney localize mainly in glomeruli,
local concentration of such cells can be relatively high. Bone
marrow cell suspensions contain different cells that may
survive for a time, and eventually engraft into glomeruli,
thereby participating in matrix production. As adipose
tissue-derived mesenchymal cells are infused as a pure cell
population, their intrinsic tendency to differentiate into
adipocytes when administered in high numbers can occur in
glomeruli.20 Such therapeutic protocols should obviously be
used with caution.
In conclusion, SC therapies can be beneficial in renal as
well as in cardiac disorders. Despite differences in structure,
embryonic origin, and function, the introduction of BM
mononuclear cells, potentially enriched in mSCs, seems to
stimulate resident stem cells and other cells in both organs to
react to cell injury and inflammation. This action promotes
both ordered organ protection and regeneration after injury.
In the kidney, the major cytoprotective effect was mediated
by decreased apoptosis, followed by an intense mobilization
of resident nestin-positive progenitors and active regenera-
tion of tubular structures. Increased angiogenesis appeared
to be an important effect, as well as decreased fibrosis and
inflammation. In the myocardium, where resident cardiac
SCs are a relatively minor population, and where the micro-
vascular density of the coronary circulation is normally
very high, we believe that angiogenesis is the primary and
major regenerative event, followed by the in situ increase
of perivascular mSCs that are required for neo-cardio-
myogenesis.
Although cellular and molecular mechanisms involved
have to be better understood, well-designed experimental and
clinical protocols with mSCs or other progenitor cells are
expected to shed more light on their therapeutic capacity in
patients with severe renal lesions. Despite technical limita-
tions and ethical concerns, SC therapy seems to provide the
hope of patient-specific renal repair in diseases in which
currently available therapies remain essentially ineffective.
DISCLOSURE
This work was supported by the Brazilian Ministry of Science and
Technology (MCT-CNPq) and by the Rio de Janeiro State Government
(FAPERJ). RB has also received grants from FAERJ and CNPq. RB is also
a coauthor of a patent covering immunization of dogs against
visceral leishmaniasis using a novel glycoconjugate.
REFERENCES
1. Bartunek J, Dimmeler S, Drexler H et al. The consensus of the task force
of the European Society of Cardiology concerning the clinical
investigation of the use of autologous adult stem cells for repair of
the heart. Eur Heart J 2006; 27: 1338–1340.
2. Menasche´ P, Hagege AA, Scorsin M et al. Myoblast transplantation for
heart failure. Lancet 2001; 357: 279–280.
3. van den Bos EJ, van der Giessen WJ, Duncker DJ. Cell transplantation
for cardiac regeneration: where do we stand? Neth Heart J 2008; 16: 88–95.
4. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;
451: 937–942.
5. Thiele J, Varus E, Wickenhauser C et al. Mixed chimerism of
cardiomyocytes and vessels after allogeneic bone marrow and stem cell
transplantation in comparison with cardiac allografts. Transplantation
2004; 77: 1902–1905.
6. Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult
cardiac stem cells from human and murine heart. Circ Res 2004; 95: 911–921.
7. Limana F, Zacheo A, Mocini D et al. Identification of myocardial and
vascular precursor cells in human and mouse epicardium. Circ Res 2007;
101: 1255–1265.
8. Perin EC, Dohmann HFR, Borojevic R et al. Improved exercise capacity
and ischemia 6 and 12 months after transendocardial injection of
autologous bone marrow mononuclear cells for ischemic
cardiomyopathy. Circulation 2004; 110-S1: 213–218.
9. Pelacho B, Prosper F. Stem cells and cardiac disease: where are we going?
Curr Stem Cell Res Ther 2008; 3: 265–276.
10. Dohmann HFR, Perin EC, Takiya CM et al. Transendocardial autologous
bone marrow mononuclear cell injection in ischemic heart failure:
postmortem anatomopathological and immunohistochemical findings.
Circulation 2005; 112: 521–526.
11. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of
mesenchymal stem cells. Stem Cells 2008; 26: 2287–2299.
Kidney International Supplements (2011) 1, 99–102 101
CM Takiya and R Borojevic: Cardiac and renal cell therapies m in i rev iew
12. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:
932–936.
13. Gupta S, Verfaillie C, Chmielewski D et al. A role of extrarenal cells in the
regeneration following acute renal failure. Kidney Int 2002; 62: 1285–1290.
14. Hayakawa M, Ishizaki M, Hayakawa J et al. Role of bone marrow cells
in the healing process of mouse experimental glomerulonephritis.
Pediatr Res 2005; 58: 323–328.
15. Broekema M, Harmsen MC, Koerts JA et al. Determinants of tubular bone
marrow-derived cell engraftment after renal ischemia/reperfusion in rats.
Kidney Int 2005; 68: 2572–2581.
16. Bussolati B, Tetta C, Camussi G. Contribution of stem cells to kidney
repair. Am J Nephrol 2008; 28: 813–822.
17. Patschan D, Michurina T, Shi HK et al. Normal distribution and medullary-
to-cortical shift of nestin-expressing cells in acute renal ischemia.
Kidney Int 2007; 71: 744–754.
18. Morigi M, Imberti B, Zoja C et al. Mesenchymal stem cells are renotropic,
helping to repair the kidney and improve function in acute renal
failure. J Am Soc Nephrol 2004; 15: 1794–1804.
19. Broekema M, Harmsen MC, Koerts JA et al. Tubular engraftment and
myofibroblast differentiation of recipient-derived cells after experimental
kidney transplantation. Transplantation 2007; 84: 1003–1011.
20. Baptista LS, Pedrosa CDG, Silva KR et al. Bone marrow and adipose tissue-
derived mesenchymal stem cells: how close are they? J Stem Cells 2007; 2:
73–90.
102 Kidney International Supplements (2011) 1, 99–102
min i rev iew CM Takiya and R Borojevic: Cardiac and renal cell therapies
